Summary
BeOne Medicines Ltd. (ONC) announced on December 30, 2019, that its anti-PD-1 antibody, tislelizumab, received approval from the China National Medical Products Administration (NMPA) for the treatment of classical Hodgkin’s lymphoma (cHL) in patients who have undergone at least two prior therapies. This marks a significant milestone as tislelizumab is BeiGene's first drug to receive approval in China, following the recent U.S. FDA approval of BRUKINSA™ (zanubrutinib). The NMPA had previously granted priority review to the new drug application (NDA), underscoring the importance of this therapy. This approval represents a key step in BeiGene's commercialization strategy in China, a major global market. The company's ability to secure regulatory approval for tislelizumab in China, especially with priority review, suggests strong clinical data and a potentially significant market opportunity for this oncology asset. Investors should monitor the market uptake and commercial performance of tislelizumab in China, as well as its potential for future indications and global market expansion.
Key Highlights
- 1Tislelizumab, an anti-PD-1 antibody, has been approved by China's NMPA for classical Hodgkin's lymphoma (cHL).
- 2This is BeiGene's first drug approval in China.
- 3The approved indication is for cHL patients who have received at least two prior therapies.
- 4The NDA for tislelizumab received priority review from the NMPA.
- 5This approval follows the recent U.S. FDA approval of BRUKINSA™ (zanubrutinib).